F. Hoffmann-La Roche AG announced on Tuesday that it is acquiring Poseida Therapeutics Inc. for around $9 per share in cash or $1 billion in total. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the deal value up to $1.5 billion. The transaction is expected to close in the first quarter of 2025.
The two companies have collaborated since 2022 on developing off-the-shelf CAR-T cell therapies for patients with hematological malignancies. “This exciting acquisition will allow us to drive further progress in allogeneic cell therapy while leveraging the successful existing partnership with Poseida,” said Roche Chief Medical Officer Levi Garraway said.
Roche's stock lost 1.14% at 9:18 am CET, while Poseida jumped 11.19% in aftermarket trade.
